Regulatory Deadline Board/2026-19563
Food and Drug Administration · Notice
Improving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Information
11 days left
In plain English
HHS is asking how deceased-donor islet cells for Type 1 diabetes should be regulated, including whether unmodified isolates should be treated differently from modified products.
Who it hits
Cell therapy sponsors, transplant programs, diabetes clinics, and islet processing labs.
- Agency
- Food and Drug Administration
- Document type
- Notice
- Published
- Sep 24, 2026
- Comments close
- Nov 9, 2026
- Status
- 11 days left
- Federal Register number
- 2026-19563
- Docket
- Docket No. FDA-2026-N-10738
More from Food and Drug Administration
Notice · 60 days left
Electronic Submission Template for Investigational Device Exemption (IDE) Applications; Draft Guidance for Sponsors and Food and Drug Administration Staff; Availability
Notice · 29 days left
Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry; Availability
Notice · 19 days left
Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff; Availability
Notice · 12 days left
Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Tracking
Notice · 5 days left
Establishment of a Quantitative Medicine Innovation Network: Scope, Feasibility, and Opportunities; Request for Information
Proposed Rule · Closed 13 days ago
Medical Devices; Classification of Accessories Distinct From Other Devices; Proposed List of Accessories Suitable for Class I; Request for Comments